<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679380</url>
  </required_header>
  <id_info>
    <org_study_id>CB-01-02/02</org_study_id>
    <nct_id>NCT00679380</nct_id>
  </id_info>
  <brief_title>(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis</brief_title>
  <official_title>Efficacy and Safety of Oral Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg Extended Release Tablets in Patients With Mild or Moderate Active Ulcerative Colitis. A Multicentre, Randomised, Double-Blind, Double-Dummy, Comparative Study Versus Placebo With an Additional Reference Arm Evaluating Entocort®EC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cosmo Technologies Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a multicentre, randomised, double-blind, double-dummy, parallel group
      comparative study in patients with mild or moderate, active ulcerative colitis. The study
      will compare budesonide-MMX™ 6 mg and budesonide-MMX™ 9 mg tablets to placebo and to
      Entocort® 3 x 3 mg capsules, in four parallel groups of patients over an 8 week treatment
      period.

      After the screening visit, patients will enter a washout period of 2 days, then they will be
      randomised to the following four treatment groups: budesonide-MMX™ tablets (6 mg),
      budesonide-MMX™ tablets (9 mg), Entocort® capsules (3 x 3 mg) and placebo (tablets and
      capsules), all administered once a day after breakfast. Hence, each patient will receive, in
      the morning after breakfast, either one budesonide-MMX™ 6 mg or budesonide MMX™ 9 mg tablet
      and 3 placebo Entocort® matching capsules, or three Entocort® 3 mg capsules and one placebo
      budesonide-MMX™ matching tablet, or one placebo budesonide-MMX™ matching tablet and three
      placebo Entocort® matching capsules.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient will receive one of the following regimens in the morning after breakfast:

        1. One budesonide MMX® 6 mg tablet plus three placebo Entocort enteric-coated (EC®)
           overencapsulated capsules, or

        2. One budesonide MMX® 9 mg tablet plus three placebo Entocort EC® overencapsulated
           capsules, or

        3. Three placebo Entocort EC® overencapsulated capsules plus one placebo budesonide MMX®
           tablet, or

        4. Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX®
           tablet, daily for eight weeks.

      Hence, each patient is to take four tablets/capsules per day of active or placebo study
      medication as per the randomization schedule. Placebo tablets of Budesonide MMX® and placebo
      overencapsulated capsules of Entocort EC® will be used to maintain the study blind using a
      double-dummy technique.

      During the study, five visits to the clinical center are scheduled: one at Screening and
      three in the double-blind treatment period (Day 1, Day 14, Day 28 and Day 56). A safety
      follow-up visit will take place about 2 weeks after the final study visit. If a patient is
      withdrawn from the study before Day 56, they will be asked to attend the study center as soon
      as possible thereafter so that the Final visit assessments can be conducted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and Endoscopic Remission.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical and endoscopic remission defined as an Ulcerative Colitis Disease Activity Index (UCDAI) score ≤ 1, with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance and with a ≥ 1 point reduction in the endoscopic index score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical improvement, defined as a ≥ 3-point improvement in UCDAI from baseline to the end of Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Improvement.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Greater or equal to a 1 point improvement in the mucosal appearance subscore of the UCDAI, from baseline to week 8.
As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">514</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>1: budesonide-MMX® 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: budesonide-MMX® 9 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Entocort EC® 3 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling, endoscopy</intervention_name>
    <description>Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores</description>
    <arm_group_label>1: budesonide-MMX® 6 mg</arm_group_label>
    <arm_group_label>2: budesonide-MMX® 9 mg</arm_group_label>
    <arm_group_label>3: Entocort EC® 3 mg</arm_group_label>
    <arm_group_label>4: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide MMX® 6 mg</intervention_name>
    <description>6 mg/day, 6 mg tablets</description>
    <arm_group_label>1: budesonide-MMX® 6 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide MMX® 9 mg</intervention_name>
    <description>9 mg/day, 9 mg tablets</description>
    <arm_group_label>2: budesonide-MMX® 9 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entocort EC® 3 mg</intervention_name>
    <description>9 mg/day, 3 mg tablets</description>
    <arm_group_label>3: Entocort EC® 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>4: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilling the following criteria at the screening visit are eligible for
             participation in the study:

               -  Male and female patients, 18-75 years old, suffering from ulcerative colitis for
                  at least 6 months.

               -  Diagnosis of ulcerative colitis in active phase, of mild or moderate entity with
                  Ulcerative Colitis Disease Activity Index (UCDAI) ≥ 4 and ≤ 10 according to
                  Sutherland.

               -  All females of child-bearing potential must have a negative serum pregnancy test
                  immediately prior to enrollment. In addition, all females of child-bearing
                  potential must agree to be completely abstinent or be using an accepted form of
                  contraception throughout the entire study period. Accepted forms of contraception
                  are defined as those with a failure rate &lt;1% when properly applied and include:
                  combination oral pill, some intra-uterine devices, and a sterilised partner in a
                  stable relationship. Female subjects must also not be actively breast-feeding
                  through the entire study period.

               -  Ability to comprehend the full nature and purpose of the study, including
                  possible risks and side effects.

               -  Ability to co-operate with the investigator and to comply with the requirements
                  of the entire study.

               -  Must be able to understand and voluntarily sign written informed consent prior to
                  inclusion in the study.

        Exclusion Criteria:

          -  Patients who meet any of the following criteria at screening visit are to be excluded
             from study participation:

               -  Patients with limited distal proctitis (from anal verge up to 15 cm above the
                  pectineal line).

               -  Patients with severe ulcerative colitis (UCDAI &gt;10).

               -  Patients with infectious colitis.

               -  Evidence or history of toxic megacolon.

               -  Severe anaemia, leucopaenia or granulocytopaenia.

               -  Use of oral or rectal steroids in the last 4 weeks.

               -  Use of immuno-suppressive agents in the last 8 weeks before the study.

               -  Use of anti tumour necrosis factor alpha (anti-TNFα) agents in the last 3 months.

               -  Concomitant use of any rectal preparation.

               -  Concomitant use of antibiotics.

               -  Concurrent use of cytochrome P450 3A4 (CYP3A4) inducers or CYP3A4 inhibitors.

               -  Patients with verified, presumed or expected pregnancy or ongoing lactation.

               -  Patients with liver cirrhosis, or evident hepatic or renal disease or
                  insufficiency, and/or severe impairment of the bio-humoural parameters (i.e. 2 x
                  upper limit of normal for alanine aminotransferase (ALT), aspartate
                  aminotransferase (AST), gamma-glutamyl transpeptidase (GGT) or creatinine).

               -  Patient with severe diseases in other organs and systems.

               -  Patients with local or systemic complications or other pathological states
                  requiring a therapy with corticosteroids and/or immuno-suppressive agents.

               -  Patients diagnosed with type 1 diabetes.

               -  Patients diagnosed with, or with a family history of, glaucoma.

               -  All patients with known hepatitis B, hepatitis C or with human immunodeficiency
                  virus (HIV), according to the local privacy policy.

               -  Participation in experimental therapeutic studies in the last 3 months. (Note:
                  patients who participated in observational only studies are not excluded).

               -  Any other medical condition that in the principal investigator's opinion would
                  make the administration of the study drug or study procedures hazardous to the
                  subject or obscure the interpretation of adverse events (AEs).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Travis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Digestive Diseases</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2046</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital, Department of Gastroenterology Clive Ward Centre,</name>
      <address>
        <city>Box Hill</city>
        <zip>VIC 3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Viru Central Hospital</name>
      <address>
        <city>Kohtla-Jarve</city>
        <zip>30322</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaron Niv</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRO - IRCCS - Struttura Operativa Complessa di Gastroenterologia Oncologica</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Interna e Specialità Mediche (DIMI)</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Gastroenterologia - Istituto Clinico Humanitas IRCCS in Gastroenterologia</name>
      <address>
        <city>Milan</city>
        <zip>20098</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daugavpils Regional Hospital</name>
      <address>
        <city>Daugavpils</city>
        <zip>5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paula Stradina Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Centre Gastro</name>
      <address>
        <city>Riga</city>
        <zip>1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical University Hospital Gailezers</name>
      <address>
        <city>Riga</city>
        <zip>1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaunas Medical University Hospital</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siauliai District Hospital</name>
      <address>
        <city>Siauliai</city>
        <zip>76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.Marcinkeviciaus Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>03215</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>03-580</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Leczenia Chorób Cywilizacyjnych</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastromed S.C.</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-842</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastromed S.C.Maciej Kralisz, Andrzej Penpicki, Jacek Romatowski, Gabinet, Gastrologiczny i Pracownia Endoskopowa</name>
      <address>
        <city>Bialystok</city>
        <zip>15-842</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Leczenia Chorob Cywilizacyjnych, oddzial Gdynia, filia Fikakw</name>
      <address>
        <city>Gdynia</city>
        <zip>81-572</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Leczenia Chorob Cywilizacyjnych</name>
      <address>
        <city>Gdynia</city>
        <zip>81-572</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Kliniki Gastroenterologii, Hepatologii i Chorob Zakaznych,</name>
      <address>
        <city>Krakow</city>
        <zip>31-531</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie,Oddział Kliniczny Kliniki Gastroenterologii Hematologii i Chorób Zakaźnych</name>
      <address>
        <city>Kraków</city>
        <zip>31-531</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej POLIMEDICA</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoskopia Sp. z o.o.</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoskopia Sp.z o.o.</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>Wejherowo</city>
        <zip>84-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Polimedica</name>
      <address>
        <city>Łódź</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Colentina Sectia Gastroenterologie</name>
      <address>
        <city>Bucuresti</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean Sibiu</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul de Gastroenterologie Dr. Goldis Adrian</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution ?National Medical Surgical Center</name>
      <address>
        <city>Moscow</city>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GU research educational medical centre of the administration of the affairs of the president of Russian Federation on the basis of State Healthcare Institution &quot;State Clinical Hospital # 51&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Scientific Centre of Coloproctology of the Federal Agency for High-Technology Medical Care</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ of Moscow &quot;City Clinical Hospital #24&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>127006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg GUZ City polyclinic #38 28</name>
      <address>
        <city>St Petersburg</city>
        <zip>193015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Medical Academy n.a. I.I. Mechnikov</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krestovsky Ireland Medical Institute</name>
      <address>
        <city>St-Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGU North-West DIstrict Medical Center of Roszdrav</name>
      <address>
        <city>St-Petersburg</city>
        <zip>199004</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZAO Clinic Dvizhenie</name>
      <address>
        <city>Volgograd</city>
        <zip>400107</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Region Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FNsP Bratislava, Nemocnica Stare Mesto 1st Internal Clinic Mickiewiczova</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FNsP Bratislava, Nemocnica Ruzinov V. Interna klinika, Gastroenterohepatologicke oddelenie Ruzinovska</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologické a Hepatologické centrum</name>
      <address>
        <city>Nitra</city>
        <zip>94901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NsP Nove Mesto nad Vahom n.o.</name>
      <address>
        <city>Nové Mesto nad Váhom</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Univerity Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IBD-Unit, Sophiahemmet</name>
      <address>
        <city>Stockholm</city>
        <zip>11486</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div. of Gastroenterology and Hepatology</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Gastroenerology and Hepatology</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chair of Gastroenterology and therapy of Dnipropetrovsk State Medical Academy based on Institute of gastroenterology</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49074</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Emergency Hospital named after O.I.Meschaninov,</name>
      <address>
        <city>Kharkov</city>
        <zip>61018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv National Medical University after name Danylo Halytsky based on Communal Clinical City hospital No 5, Department of Propedeutic of Internal Disease</name>
      <address>
        <city>Lviv</city>
        <zip>79013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odessa city Polyclinic #20, Therapeutic Dept. 6</name>
      <address>
        <city>Odessa</city>
        <zip>65114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzhgorod National University, Hospital surgery chair on the base of Uzhgorod Regional Clinical Hospital</name>
      <address>
        <city>Uzhorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzhgorod State Medical University, chair of therapy and family medicine, district clinical hospitalof station &quot;Uzhgorod&quot;</name>
      <address>
        <city>Uzhorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Headington</city>
        <state>Oxford</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Unit</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Marks Hospital</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2008</study_first_posted>
  <results_first_submitted>April 25, 2014</results_first_submitted>
  <results_first_submitted_qc>July 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2014</results_first_posted>
  <disposition_first_submitted>December 1, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 9, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 13, 2012</disposition_first_posted>
  <last_update_submitted>July 3, 2014</last_update_submitted>
  <last_update_submitted_qc>July 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited from July 2008 to February 2010.</recruitment_details>
      <pre_assignment_details>3 randomized patients were not treated and are excluded from all analyses. The safety population, N= 511: 509 randomized and treated + 2 nonrandomized and treated patients. The intent-to-treat (ITT) population, N=410: 511 - 101 patients who were not randomized, had major entry criteria violation, GCP violation, or normal histology at baseline.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1: Budesonide-MMX® 6 mg</title>
          <description>One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
        </group>
        <group group_id="P2">
          <title>2: Budesonide-MMX® 9 mg</title>
          <description>One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
        </group>
        <group group_id="P3">
          <title>3: Entocort EC® 3 mg</title>
          <description>Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.</description>
        </group>
        <group group_id="P4">
          <title>4: Placebo</title>
          <description>Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="103"/>
                <participants group_id="P4" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics were analyzed with the ITT population, defined as randomized patients who received study drug, had no entry criteria/GCP violation, and had abnormal mucosal histology at baseline. ITT population=410 patients: 511 - 101 patients who were not randomized, had entry criteria/GCP violation, or had normal histology at baseline.</population>
      <group_list>
        <group group_id="B1">
          <title>1: Budesonide-MMX® 6 mg</title>
          <description>One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
        </group>
        <group group_id="B2">
          <title>2: Budesonide-MMX® 9 mg</title>
          <description>One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
        </group>
        <group group_id="B3">
          <title>3: Entocort EC® 3 mg</title>
          <description>Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.</description>
        </group>
        <group group_id="B4">
          <title>4: Placebo</title>
          <description>Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="109"/>
            <count group_id="B3" value="103"/>
            <count group_id="B4" value="89"/>
            <count group_id="B5" value="410"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="13.6"/>
                    <measurement group_id="B2" value="42.8" spread="13.9"/>
                    <measurement group_id="B3" value="43.4" spread="14.0"/>
                    <measurement group_id="B4" value="44.8" spread="13.0"/>
                    <measurement group_id="B5" value="43.6" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical and Endoscopic Remission.</title>
        <description>Clinical and endoscopic remission defined as an Ulcerative Colitis Disease Activity Index (UCDAI) score ≤ 1, with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance and with a ≥ 1 point reduction in the endoscopic index score.</description>
        <time_frame>8 weeks</time_frame>
        <population>Efficacy endpoints were analyzed with the ITT population, defined as randomized patients who received study drug, had no entry criteria/GCP violation, and had abnormal mucosal histology at baseline. ITT population=410 patients: 511 - 101 patients who were not randomized, had entry criteria/GCP violation, or had normal histology at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Budesonide-MMX® 6 mg</title>
            <description>One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
          </group>
          <group group_id="O2">
            <title>2: Budesonide-MMX® 9 mg</title>
            <description>One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
          </group>
          <group group_id="O3">
            <title>3: Entocort EC® 3 mg</title>
            <description>Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.</description>
          </group>
          <group group_id="O4">
            <title>4: Placebo</title>
            <description>Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical and Endoscopic Remission.</title>
          <description>Clinical and endoscopic remission defined as an Ulcerative Colitis Disease Activity Index (UCDAI) score ≤ 1, with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance and with a ≥ 1 point reduction in the endoscopic index score.</description>
          <population>Efficacy endpoints were analyzed with the ITT population, defined as randomized patients who received study drug, had no entry criteria/GCP violation, and had abnormal mucosal histology at baseline. ITT population=410 patients: 511 - 101 patients who were not randomized, had entry criteria/GCP violation, or had normal histology at baseline.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="3.1" upper_limit="13.4"/>
                    <measurement group_id="O2" value="17.4" lower_limit="10.3" upper_limit="24.6"/>
                    <measurement group_id="O3" value="12.6" lower_limit="6.2" upper_limit="19.0"/>
                    <measurement group_id="O4" value="4.5" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All p-values were based on the Chi-square test; comparisons of budesonide MMX and placebo were conducted at the α = 0.025 level of significance and the comparison of Entocort EC and placebo were conducted at the α = 0.05 level of significance. The study was not powered to show statistical significance for Entocort EC versus budesonide MMX.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2876</p_value>
            <p_value_desc>P-Value was adjusted for multiple comparisons; two dosage strengths were compared with placebo.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
            <estimate_desc>The difference in proportions was determined by subtracting the proportion of patients who reached the endpoint in the placebo group from that proportion in the active group (active minus placebo).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0047</p_value>
            <p_value_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>12.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.6</ci_lower_limit>
            <ci_upper_limit>21.3</ci_upper_limit>
            <estimate_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0481</p_value>
            <p_value_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>8.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>15.9</ci_upper_limit>
            <estimate_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement.</title>
        <description>Clinical improvement, defined as a ≥ 3-point improvement in UCDAI from baseline to the end of Week 8.</description>
        <time_frame>8 weeks</time_frame>
        <population>Efficacy endpoints were analyzed with the ITT population, defined as randomized patients who received study drug, had no entry criteria/GCP violation, and had abnormal mucosal histology at baseline. ITT population=410 patients: 511 - 101 patients who were not randomized, had entry criteria/GCP violation, or had normal histology at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Budesonide-MMX® 6 mg</title>
            <description>One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
          </group>
          <group group_id="O2">
            <title>2: Budesonide-MMX® 9 mg</title>
            <description>One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
          </group>
          <group group_id="O3">
            <title>3: Entocort EC® 3 mg</title>
            <description>Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.</description>
          </group>
          <group group_id="O4">
            <title>4: Placebo</title>
            <description>Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement.</title>
          <description>Clinical improvement, defined as a ≥ 3-point improvement in UCDAI from baseline to the end of Week 8.</description>
          <population>Efficacy endpoints were analyzed with the ITT population, defined as randomized patients who received study drug, had no entry criteria/GCP violation, and had abnormal mucosal histology at baseline. ITT population=410 patients: 511 - 101 patients who were not randomized, had entry criteria/GCP violation, or had normal histology at baseline.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" lower_limit="17.5" upper_limit="33.9"/>
                    <measurement group_id="O2" value="42.2" lower_limit="32.9" upper_limit="51.5"/>
                    <measurement group_id="O3" value="33.0" lower_limit="23.9" upper_limit="42.1"/>
                    <measurement group_id="O4" value="33.7" lower_limit="23.9" upper_limit="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Clinical improvement and endoscopic improvement were analyzed hierarchically. If at least one primary endpoint comparison was statistically significant, clinical improvement was to be compared between each budesonide MMX group and placebo at the α = 0.025 level of significance. If at least one comparison of clinical improvement was statistically significant, endoscopic improvement was to be compared between each budesonide MMX dose group and placebo at the α = 0.025 level of significance.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2174</p_value>
            <p_value_desc>P-Value was adjusted for multiple comparisons; two dosage strengths were compared with placebo.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>-8.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.8</ci_lower_limit>
            <ci_upper_limit>4.</ci_upper_limit>
            <estimate_desc>The difference in proportions was determined by subtracting the proportion of patients who reached the endpoint in the placebo group from that proportion in the active group (active minus placebo).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2215</p_value>
            <p_value_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>8.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>22.0</ci_upper_limit>
            <estimate_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9185</p_value>
            <p_value_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.1</ci_lower_limit>
            <ci_upper_limit>12.7</ci_upper_limit>
            <estimate_desc>See comments from the budesonide 6 mg versus placebo comparison (statistical analysis 1).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endoscopic Improvement.</title>
        <description>Greater or equal to a 1 point improvement in the mucosal appearance subscore of the UCDAI, from baseline to week 8.
As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted.</description>
        <time_frame>8 weeks</time_frame>
        <population>Efficacy endpoints were analyzed with the ITT population, defined as randomized patients who received study drug, had no entry criteria/GCP violation, and had abnormal mucosal histology at baseline. ITT population=410 patients: 511 - 101 patients who were not randomized, had entry criteria/GCP violation, or had normal histology at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Budesonide-MMX® 6 mg</title>
            <description>One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
          </group>
          <group group_id="O2">
            <title>2: Budesonide-MMX® 9 mg</title>
            <description>One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
          </group>
          <group group_id="O3">
            <title>3: Entocort EC® 3 mg</title>
            <description>Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.</description>
          </group>
          <group group_id="O4">
            <title>4: Placebo</title>
            <description>Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopic Improvement.</title>
          <description>Greater or equal to a 1 point improvement in the mucosal appearance subscore of the UCDAI, from baseline to week 8.
As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted.</description>
          <population>Efficacy endpoints were analyzed with the ITT population, defined as randomized patients who received study drug, had no entry criteria/GCP violation, and had abnormal mucosal histology at baseline. ITT population=410 patients: 511 - 101 patients who were not randomized, had entry criteria/GCP violation, or had normal histology at baseline.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" lower_limit="17.5" upper_limit="33.9"/>
                    <measurement group_id="O2" value="42.2" lower_limit="32.9" upper_limit="51.5"/>
                    <measurement group_id="O3" value="36.9" lower_limit="27.6" upper_limit="46.2"/>
                    <measurement group_id="O4" value="31.5" lower_limit="21.8" upper_limit="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted. The statistical comparison between the Entocort EC and placebo groups is shown here.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4293</p_value>
            <p_value_desc>P-Value was adjusted for multiple comparisons; two budesonide dosage strengths were compared with placebo.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Difference in proportions</param_type>
            <param_value>5.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>18.8</ci_upper_limit>
            <estimate_desc>The difference in proportions was determined by subtracting the proportion of patients who reached the endpoint in the placebo group from that proportion in the active group (active minus placebo).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>56 day ± 2 day (study duration) + 30 day safety followup period.</time_frame>
      <desc>Adverse event data were analyzed using the safety population, defined as all patients who received study drug. N= 511 for the safety population: 509 randomized and treated + 2 nonrandomized and treated patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>1: Budesonide-MMX® 6 mg</title>
          <description>One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
        </group>
        <group group_id="E2">
          <title>2: Budesonide-MMX® 9 mg</title>
          <description>One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.</description>
        </group>
        <group group_id="E3">
          <title>3: Entocort EC® 3 mg</title>
          <description>Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.</description>
        </group>
        <group group_id="E4">
          <title>4: Placebo</title>
          <description>Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA V11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Treatment failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Signet-ring cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA V11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E3" events="14" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="128"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="128"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="126"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E2" events="18" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E3" events="16" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="128"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="128"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Treatment failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="128"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cortisol decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="30" subjects_affected="21" subjects_at_risk="128"/>
                <counts group_id="E2" events="35" subjects_affected="20" subjects_at_risk="128"/>
                <counts group_id="E3" events="15" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E4" events="11" subjects_affected="8" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Huang, M.D., Senior Medical Director</name_or_title>
      <organization>Santarus, Inc.</organization>
      <phone>858-314-5700</phone>
      <email>contact@santarus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

